Risk of active tuberculosis in patients with cancer: a systematic review and metaanalysis

MP Cheng, CNA Chakra, CP Yansouni… - Clinical Infectious …, 2017 - academic.oup.com
Background. Cancer is a known risk factor for developing active tuberculosis. We
determined the incidence and relative risk of active tuberculosis in cancer patients …

Immunotherapy and Biomarkers in Lung Cancer Patients with Tuberculosis: Recent Advances and Future Directions

L Yang, L Zhuang, Z Ye, L Li, J Guan, W Gong - Iscience, 2023 - cell.com
Lung cancer (LC) and tuberculosis (TB) are two major global public health problems, and
the incidence of LC-TB is currently on the rise. Therefore effective clinical interventions are …

Tuberculosis and risk of cancer: A systematic review and meta-analysis

P Luczynski, P Poulin, K Romanowski, JC Johnston - Plos one, 2022 - journals.plos.org
Introduction Cancer is a major cause of death among people who experience tuberculosis
(TB), but little is known about its timing and incidence following TB treatment. Our primary …

[HTML][HTML] Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study

JY Feng, SF Huang, WY Ting, YC Chen, YY Lin… - Clinical Microbiology …, 2012 - Elsevier
Gender disparities in tuberculosis (TB) cases are reported worldwide, and socio-cultural
factors have been proposed as possible causes. To date, gender differences in treatment …

The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse

CC Shu, KM Liao, YC Chen, JJ Wang, CH Ho - Scientific reports, 2019 - nature.com
Population with malignancy is growing worldwide; however, its tuberculosis (TB) burden
including remains unclear regarding incidence, mortality, and relapse. We retrieved …

Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review

AM Suliman, SA Bek, MS Elkhatim, AA Husain… - Cancer Immunology …, 2021 - Springer
Immune checkpoint inhibitors (ICIs)—anti-programmed death-1 (PD-1) and their ligands (PD-
L1 and PD-L2) have become widely used in the treatment of several malignancies. Many …

[HTML][HTML] Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study

S Bae, YJ Kim, M Kim, JH Kim, SC Yun… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background While some recent studies have reported the development of tuberculosis (TB)
in patients exposed to immune checkpoint inhibitors (ICIs), there is limited evidence to date …

Dual nature of relationship between mycobacteria and cancer

M Fol, P Koziński, J Kulesza, P Białecki… - International Journal of …, 2021 - mdpi.com
Although the therapeutic effect of mycobacteria as antitumor agents has been known for
decades, recent epidemiological and experimental studies have revealed that …

Aerodigestive tract, lung and haematological cancers are risk factors for tuberculosis: an 8-year population-based study

CY Wu, HY Hu, CY Pu, N Huang… - … of tuberculosis and …, 2011 - ingentaconnect.com
SETTING: The deterioration of immunity in cancer patients may be associated with a higher
incidence of tuberculosis (TB). OBJECTIVE: Despite several previous studies on cancer and …

Risk factors for pulmonary tuberculosis in Croatia: a matched case–control study

A Jurcev-Savicevic, R Mulic, B Ban, K Kozul… - BMC public health, 2013 - Springer
Background Mycobacterium tuberculosis is a necessary, but not sufficient, cause of
tuberculosis. A number of studies have addressed the issue of risk factors for tuberculosis …